Hepanib 200 mg (Tablet)

Unit Price: ৳ 180.00 (1 x 28: ৳ 5,040.00)
Strip Price: ৳ 5,040.00

Medicine Details

Category Details
Generic Sorafenib tosylate
Company Everest pharmaceuticals ltd

Indications

  • Hepatocellular Carcinoma
  • Renal Cell Carcinoma

Pharmacology

  • Kinase inhibitor
  • Tumor cell proliferation reduction
  • Inhibition of multiple intracellular and cell surface kinases

Dosage & Administration

  • Recommended daily dose of 400 mg tablets taken twice daily without food
  • Temporary interruption and/or dose reduction may be required for adverse drug reactions
  • Missed doses should be skipped, and the next dose should be taken at the regular time

Interaction

  • Contraindicated in combination with carboplatin and paclitaxel in patients with squamous cell lung cancer
  • Systemic exposure to UGT1A1 and UGT1A9 substrates may increase when co-administered
  • Caution is recommended when co-administered with docetaxel, doxorubicin, fluorouracil, and other substrates/inducers/inhibitors of CYP enzymes and P-glycoprotein
  • No effect on the pharmacokinetics of gemcitabine or oxaliplatin
  • Concomitant use with oral neomycin should be carefully considered

Contraindications

  • Severe hypersensitivity to Sorafenib or any other component
  • Contraindicated in combination with carboplatin and paclitaxel in patients with squamous cell lung cancer

Side Effects

  • Cardiac ischemia
  • Infarction
  • Hemorrhage
  • Hypertension
  • Hand-foot skin reaction and rash
  • Gastrointestinal perforation
  • Wound healing complications

Pregnancy & Lactation

  • May cause fetal harm when administered to a pregnant woman
  • Women of childbearing potential should be advised to avoid becoming pregnant while on Sorafenib
  • Not known whether Sorafenib is excreted in human milk

Precautions & Warnings

  • Consider discontinuation in case of cardiac ischemia and/or infarction
  • Increased risk of bleeding, hypertension, dermatologic toxicities, and gastrointestinal perforation
  • Regular monitoring for patients taking concomitant warfarin
  • Advisable to resume therapy following major surgical intervention based on adequate wound healing
  • Caution in combination with carboplatin and paclitaxel in non-small cell lung cancer
  • Increases in plasma concentrations of UGT1A1 substrates, docetaxel, and doxorubicin
  • Hepatic impairment may reduce plasma concentrations of Hepanib
  • Co-administration of oral neomycin causes a decrease in Hepanib exposure

Use in Special Populations

  • Safety and effectiveness in pediatric patients not studied
  • No differences in safety or efficacy observed between older and younger patients
  • No dose adjustment required for patients with renal impairment
  • Decreased AUC in patients with mild to moderate hepatic impairment

Overdose Effects

  • No specific treatment for overdose
  • Adverse reactions observed at highest clinically studied dose were primarily diarrhea and dermatologic

Therapeutic Class

  • Targeted Cancer Therapy

Storage Conditions

  • Store at room temperature below 30°C
  • Do not remove desiccant
  • Dispense in original bottle

Related Brands